NCT02750995View on ClinicalTrials.gov

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 2, 2018

Study Completion Date

June 1, 2019

Conditions
Myelodysplastic SyndromeAcute Myeloid Leukemia
Interventions
BIOLOGICAL

NPMW-peptide vaccine

Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.

DRUG

Azacitidine

Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.

Trial Locations (1)

2730

Dept of Hematology, Herlev Hospital, Herlev

All Listed Sponsors
collaborator

Technical University of Denmark

OTHER

lead

Daniel El Fassi

OTHER

NCT02750995 - Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML | Biotech Hunter | Biotech Hunter